Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2014 2
2015 1
2016 1
2021 2
2022 4
2023 5
2024 6
2026 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

17 results

Results by year

Filters applied: Meta-Analysis, Randomized Controlled Trial. Clear all
Page 1
Olokizumab versus Placebo or Adalimumab in Rheumatoid Arthritis.
Smolen JS, Feist E, Fatenejad S, Grishin SA, Korneva EV, Nasonov EL, Samsonov MY, Fleischmann RM; CREDO2 Group. Smolen JS, et al. N Engl J Med. 2022 Aug 25;387(8):715-726. doi: 10.1056/NEJMoa2201302. N Engl J Med. 2022. PMID: 36001712 Clinical Trial.
RESULTS: A total of 464 patients were assigned to receive olokizumab every 2 weeks, 479 to receive olokizumab every 4 weeks, 462 to receive adalimumab, and 243 to receive placebo. ...Both olokizumab doses were noninferior to adalimumab with respect to the per …
RESULTS: A total of 464 patients were assigned to receive olokizumab every 2 weeks, 479 to receive olokizumab every 4 weeks, 4 …
Olokizumab's Effectiveness and Safety in Patients with Rheumatoid Arthritis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Mahmoud AM. Mahmoud AM. J Clin Densitom. 2023 Jan-Mar;26(1):61-82. doi: 10.1016/j.jocd.2022.12.003. Epub 2022 Dec 6. J Clin Densitom. 2023. PMID: 36535857
The incidence of treatment-emergent adverse events was significantly higher in the olokizumab group than in the placebo group; RR = 1.10, 95% CI [1.04, 1.17], P = 0.0006. Furthermore, the incidence of treatment-emergent serious adverse events did not differ significantly b …
The incidence of treatment-emergent adverse events was significantly higher in the olokizumab group than in the placebo group; RR = 1 …
EFFICACY AND SAFETY OF OLOKIZUMAB IN THE MANAGEMENT OF RHEUMATOID ARTHRITIS- A SYSTEMATIC REVIEW AND META-ANALYSIS.
Khalid S, Imran L, Uzair M, Tirmizi J, Khan A, Tashkil S, Adil A. Khalid S, et al. J Ayub Med Coll Abbottabad. 2024 Jan-Mar;36(1):190-197. doi: 10.55519/JAMC-01-12456. J Ayub Med Coll Abbottabad. 2024. PMID: 39585284 Free article.
BACKGROUND: Olokizumab (OKZ) is a monoclonal antibody against the interleukin receptor-6 that has shown promise in recent phase II and III trials in patients of rheumatoid arthritis (RA). ...Safety data showed comparable mortality rates in treatment and placebo groups (OKZ …
BACKGROUND: Olokizumab (OKZ) is a monoclonal antibody against the interleukin receptor-6 that has shown promise in recent phase II an …
Olokizumab plus methotrexate: safety and efficacy over 106 weeks of treatment.
Feist E, Fleischmann RM, Fatenejad S, Bukhanova D, Grishin S, Kuzkina S, Luggen M, Nasonov E, Samsonov M, Smolen JS. Feist E, et al. Ann Rheum Dis. 2024 Oct 21;83(11):1454-1464. doi: 10.1136/ard-2023-225473. Ann Rheum Dis. 2024. PMID: 38955475 Free PMC article. Clinical Trial.
OBJECTIVE: To report long-term safety and tolerability of olokizumab (OKZ) in combination with methotrexate (MTX) in subjects with active rheumatoid arthritis (RA), using pooled data from three randomised clinical trials (RCT) followed by open-label extension (OLE) study. …
OBJECTIVE: To report long-term safety and tolerability of olokizumab (OKZ) in combination with methotrexate (MTX) in subjects with ac …
The efficacy and safety of olokizumab for rheumatoid arthritis: a systematic review, pairwise, and network meta-analysis.
Abuelazm M, Ghanem A, Mahmoud A, Brakat AM, Elzeftawy MA, Mamdouh Fayoud A, Awad AK, Abdelazeem B. Abuelazm M, et al. Clin Rheumatol. 2023 Jun;42(6):1503-1520. doi: 10.1007/s10067-023-06519-6. Epub 2023 Feb 16. Clin Rheumatol. 2023. PMID: 36792848 Free PMC article.
Olokizumab (OKZ) is a novel IL-6 inhibitor that directly targets IL-6 rather than its receptor. ...
Olokizumab (OKZ) is a novel IL-6 inhibitor that directly targets IL-6 rather than its receptor. ...
Olokizumab, a monoclonal antibody against interleukin-6, in combination with methotrexate in patients with rheumatoid arthritis inadequately controlled by tumour necrosis factor inhibitor therapy: efficacy and safety results of a randomised controlled phase III study.
Feist E, Fatenejad S, Grishin S, Korneva E, Luggen ME, Nasonov E, Samsonov M, Smolen JS, Fleischmann RM. Feist E, et al. Ann Rheum Dis. 2022 Dec;81(12):1661-1668. doi: 10.1136/ard-2022-222630. Epub 2022 Sep 15. Ann Rheum Dis. 2022. PMID: 36109142 Free PMC article. Clinical Trial.
OBJECTIVES: To assess the efficacy and safety of olokizumab (OKZ), a monoclonal antibody against the interleukin-6 (IL-6) cytokine, versus placebo (PBO) in patients with prior inadequate response to tumour necrosis factor inhibitors (TNFi-IRs). ...
OBJECTIVES: To assess the efficacy and safety of olokizumab (OKZ), a monoclonal antibody against the interleukin-6 (IL-6) cytokine, v …
Olokizumab, a monoclonal antibody against interleukin 6, in combination with methotrexate in patients with rheumatoid arthritis inadequately controlled by methotrexate: efficacy and safety results of a randomised controlled phase III study.
Nasonov E, Fatenejad S, Feist E, Ivanova M, Korneva E, Krechikova DG, Maslyanskiy AL, Samsonov M, Stoilov R, Zonova EV, Genovese M. Nasonov E, et al. Ann Rheum Dis. 2022 Apr;81(4):469-479. doi: 10.1136/annrheumdis-2021-219876. Epub 2021 Aug 3. Ann Rheum Dis. 2022. PMID: 34344706 Free PMC article. Clinical Trial.
OBJECTIVE: To evaluate the efficacy and safety of olokizumab (OKZ) in patients with active rheumatoid arthritis despite treatment with methotrexate (MTX). ...
OBJECTIVE: To evaluate the efficacy and safety of olokizumab (OKZ) in patients with active rheumatoid arthritis despite treatment wit …
Efficacy and safety of current therapies for difficult-to-treat rheumatoid arthritis: a systematic review and network meta-analysis.
Su QY, Luo J, Zhang Y, Li Q, Jiang ZQ, Wen ZR, Wang YY, Shi MR, Zhang SX. Su QY, et al. J Transl Med. 2024 Aug 28;22(1):795. doi: 10.1186/s12967-024-05569-x. J Transl Med. 2024. PMID: 39198829 Free PMC article.
The improvement of American College of Rheumatology 50 response (ACR50) score in patients with drug use was ranked from good to poor as follows: olokizumab, tocilizumab, adalimumab, baricitinib, and upadacitinib, and 8 mg/4w tocilizumab demonstrated the best efficacy. ...
The improvement of American College of Rheumatology 50 response (ACR50) score in patients with drug use was ranked from good to poor as foll …
Efficacy of Olokizumab against Comorbid Depressive Disorder in Patients with Rheumatoid Arthritis: Preliminary Results of the Study.
Lisitsyna TA, Abramkin AA, Veltishchev DY, Seravina OF, Kovalevskaya OB, Borisova AB, Ignatiev VG, Nasonov EL. Lisitsyna TA, et al. Dokl Biochem Biophys. 2024 Aug;517(1):195-206. doi: 10.1134/S160767292470090X. Epub 2024 Jun 10. Dokl Biochem Biophys. 2024. PMID: 38861142 Clinical Trial.
The objective of the study was to evaluate the effectiveness of Russian iIL-6 olokizumab (OKZ) in reducing symptoms of depression in patients with moderate/high RA activity. ...
The objective of the study was to evaluate the effectiveness of Russian iIL-6 olokizumab (OKZ) in reducing symptoms of depression in …
Comparison of the efficacy and safety of olokizumab at different dosages in patients with active rheumatoid arthritis: a network meta-analysis of randomized controlled trials.
Lee YH, Song GG. Lee YH, et al. Z Rheumatol. 2024 Feb;83(Suppl 1):107-114. doi: 10.1007/s00393-023-01367-w. Epub 2023 Jun 2. Z Rheumatol. 2024. PMID: 37266677 English.
The ranking probability based on the SUCRA indicated that olokizumab Q2W had the highest probability of being considered the best treatment option for achieving the ACR20 response rate, followed by olokizumab Q4W, adalimumab, and placebo. ...CONCLUSION: Both olok …
The ranking probability based on the SUCRA indicated that olokizumab Q2W had the highest probability of being considered the best tre …
17 results